$824 Million is the total value of VR Adviser, LLC's 29 reported holdings in Q2 2021. The portfolio turnover from Q1 2021 to Q2 2021 was 60.7% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| TIL | INSTIL BIO INC | $132,633,000 | -23.0% | 6,865,076 | 0.0% | 16.09% | -13.9% | |
| ACRS | Buy | ACLARIS THERAPEUTICS INC | $80,143,000 | -14.5% | 4,563,962 | +22.7% | 9.72% | -4.4% |
| VTGN | Sell | VISTAGEN THERAPEUTICS INC | $50,549,000 | +45.6% | 16,047,286 | -1.6% | 6.13% | +62.8% |
| GRPH | New | GRAPHITE BIO INC | $49,556,000 | – | 1,612,617 | +100.0% | 6.01% | – |
| MARINUS PHARMACEUTICALS INC | $47,394,000 | +15.9% | 2,641,809 | 0.0% | 5.75% | +29.6% | ||
| RLMD | Buy | RELMADA THERAPEUTICS INC | $44,421,000 | +47.9% | 1,387,720 | +62.6% | 5.39% | +65.3% |
| OLMA | OLEMA PHARMACEUTICALS INC | $42,983,000 | -15.7% | 1,536,193 | 0.0% | 5.21% | -5.7% | |
| CLDX | CELLDEX THERAPEUTICS INC | $41,486,000 | +62.3% | 1,240,610 | 0.0% | 5.03% | +81.5% | |
| ALT | ALTIMMUNE INC | $34,475,000 | -30.3% | 3,500,000 | 0.0% | 4.18% | -22.1% | |
| KNTE | KINNATE BIOPHARMA INC | $34,292,000 | -25.3% | 1,473,014 | 0.0% | 4.16% | -16.4% | |
| GHRS | New | GH RESEARCH PLCord sh | $27,724,000 | – | 1,275,831 | +100.0% | 3.36% | – |
| CGEM | Sell | CULLINAN ONCOLOGY INC | $25,136,000 | -48.7% | 976,145 | -17.0% | 3.05% | -42.7% |
| CNTA | New | CENTESSA PHARMACEUTICALS PLCspons ads | $25,037,000 | – | 1,127,272 | +100.0% | 3.04% | – |
| PRVB | New | PROVENTION BIO INC | $24,470,000 | – | 2,902,744 | +100.0% | 2.97% | – |
| Sell | TRILLIUM THERAPEUTICS INC | $19,416,000 | -55.3% | 2,001,686 | -50.5% | 2.36% | -50.0% | |
| EPIX | ESSA PHARMA INC | $17,878,000 | -1.7% | 625,754 | 0.0% | 2.17% | +10.0% | |
| CVRX | New | CVRX INC | $17,734,000 | – | 633,370 | +100.0% | 2.15% | – |
| PHVS | PHARVARIS NV | $16,821,000 | -33.6% | 902,882 | 0.0% | 2.04% | -25.8% | |
| ATHA | Sell | ATHIRA PHARMA INC | $15,206,000 | -51.1% | 1,485,005 | -12.2% | 1.84% | -45.4% |
| RAPT | New | RAPT THERAPEUTICS INC | $12,430,000 | – | 391,000 | +100.0% | 1.51% | – |
| KURA | KURA ONCOLOGY INC | $11,989,000 | -26.2% | 575,000 | 0.0% | 1.45% | -17.5% | |
| KROS | Sell | KEROS THERAPEUTICS INC | $11,565,000 | -49.5% | 272,306 | -26.9% | 1.40% | -43.6% |
| COGT | COGENT BIOSCIENCES INC | $8,830,000 | -7.6% | 1,088,817 | 0.0% | 1.07% | +3.3% | |
| ALGS | ALIGOS THERAPEUTICS INC | $8,325,000 | -10.3% | 408,377 | 0.0% | 1.01% | +0.3% | |
| AKYA | New | AKOYA BIOSCIENCES INC | $7,736,000 | – | 400,000 | +100.0% | 0.94% | – |
| HARP | New | HARPOON THERAPEUTICS INC | $7,102,000 | – | 512,005 | +100.0% | 0.86% | – |
| New | CATABASIS PHARMACEUTICALS INC | $6,824,000 | – | 3,234,000 | +100.0% | 0.83% | – | |
| ACET | Sell | ADICET BIO INC | $1,890,000 | -85.6% | 183,702 | -81.6% | 0.23% | -83.9% |
| VRDN | VIRIDIAN THERAPEUTICS INC | $357,000 | +9.5% | 19,495 | 0.0% | 0.04% | +22.9% | |
| TSHA | Exit | TAYSHA GENE THERAPIES INC | $0 | – | -120,649 | -100.0% | -0.27% | – |
| SBTX | Exit | SILVERBACK THERAPEUTICS INC | $0 | – | -85,000 | -100.0% | -0.40% | – |
| MTCR | Exit | METACRINE INC | $0 | – | -680,000 | -100.0% | -0.46% | – |
| BCTG | Exit | BCTG ACQUISITION CORP | $0 | – | -500,000 | -100.0% | -0.60% | – |
| EYPT | Exit | EYEPOINT PHARMACEUTICALS INC | $0 | – | -700,000 | -100.0% | -0.77% | – |
| Exit | APTOSE BIOSCIENCES INC | $0 | – | -1,605,400 | -100.0% | -1.04% | – | |
| SNDX | Exit | SYNDAX PHARMACEUTICALS INC | $0 | – | -591,782 | -100.0% | -1.44% | – |
| CNST | Exit | CONSTELLATION PHARMACEUTICAL | $0 | – | -4,016,873 | -100.0% | -10.19% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2021-08-13
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| ACLARIS THERAPEUTICS INC | 12 | Q3 2023 | 12.7% |
| VIRIDIAN THERAPEUTICS INC | 12 | Q3 2023 | 13.4% |
| COGENT BIOSCIENCES INC | 12 | Q3 2023 | 10.3% |
| RELMADA THERAPEUTICS INC | 11 | Q3 2022 | 9.9% |
| GH RESEARCH PLC | 10 | Q3 2023 | 6.7% |
| ALTIMMUNE INC | 9 | Q3 2022 | 11.6% |
| MARINUS PHARMACEUTICALS INC | 9 | Q4 2022 | 5.7% |
| CELLDEX THERAPEUTICS INC | 9 | Q3 2022 | 7.6% |
| AFFIMED N V | 8 | Q3 2023 | 1.1% |
| INSTIL BIO INC | 7 | Q3 2022 | 18.7% |
View VR Adviser, LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-11 |
| 13F-HR/A | 2023-05-15 |
| 13F-HR/A | 2023-05-15 |
| 13F-HR/A | 2023-05-15 |
| 13F-HR | 2023-05-15 |
| 13F-HR | 2023-02-14 |
| 13F-HR | 2022-11-14 |
| 13F-HR | 2022-08-15 |
View VR Adviser, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.